| Literature DB >> 28027963 |
Guillermo Orti1, Pere Barba2, Laura Fox2, Olga Salamero2, Francesc Bosch2, David Valcarcel2.
Abstract
Allogeneic hematopoietic cell transplantation (allo-HCT) represents the only curative therapy for many haematological malignancies. Its curative potential is mostly attributed to the graft-versus-leukemia effect (GvL), which is mainly driven by donor T-cells. Donor lymphocyte infusions (DLI), likewise a second allo-HCT, have become a standard approach to treat AML and MDS relapses post allo-HCT. Although DLI have been used in this setting for decades, its effectivity and toxicity are still unpredictable in many patients. Over these recent years, new DLI strategies and therapies have been developed for AML and MDS. In this review, we will overview the recent use of DLI for AML and MDS, with up to date information from novel studies and research lines.Entities:
Mesh：
Substances：
Year: 2016 PMID： 28027963 DOI： 10.1016/j.exphem.2016.12.004
Source DB: PubMed Journal: Exp Hematol ISSN： 0301-472X Impact factor: 3.084